Articles by Melissa Badamo
The results suggest a possible treatment strategy of selinexor followed by immunotherapy.
Tasquinimod inhibited interaction of A9, a protein associated with poor prognosis.
The survey examined global access to 14 chemoimmunotherapy options and autologous stem cell transplant (ASCT).
DT2216 alone was effective, but exhibited a slightly greater cell viability reduction when combined with other therapies.
Those high-risk disease features include high proliferation index, TP53 mutation, blastoid morphology, and CNS lymphoma.
The study tested the combination therapy in a patient-derived xenograft (PDX) model of NPM1-mutated AML.
One-time liso-cel infusion demonstrated durable responses in R/R LBCL.
The accelerated approval was based on efficacy results from the BRUIN trial.
Researchers assessed the number of patients who received subsequent treatment after tirabrutinib discontinuation.
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
93% of patients became measurable residual disease (MRD) negative after the first cycle of blinatumomab.
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
The multicenter trial studied genetic mutations across three cohorts.
CR rates were comparable in both treatment groups, but OS was superior in the ruxolitinib group.
The study determined the maximum tolerated dose of CPX-351, but further studies are needed to evaluate its activity.
The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Of the 200 APPs surveyed, 72% reported being “generally knowledgeable” about MM before seeing their first patient.
Early deaths remain a barrier against understanding a cure-for-all.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.